Net profit on a sequential basis declined 61 per cent

The shares of Glenmark Pharma plummeted sharply about 16 per cent on Friday on the back of disappointing fourth quarter earnings, which was released after market hours on Thursday.The March 2017 quarter numbers were much below the market expectations. While the drug maker registered a growth of 23.5 per cent year-on-year (y-o-y) in its consolidated net profit to ₹183.76 crore for the fourth quarte...